Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder

European Urology Jan 23, 2020

Necchi A, Madison R, Raggi D, et al. - Researchers designed a comparative comprehensive genomic profiling (CGP) study to analyze genomic alterations (GAs) and immuno-oncology (IO) biomarkers. They searched the Foundation Medicine database to include a sum of 143 cases with centrally reviewed pure ACB, 2,142 with pure urothelial carcinoma (UC), and 83 with pure SCC. They ascertained tumor mutational burden (TMB) on 1.1 Mbp of sequenced DNA and determined microsatellite instability (MSI) on 114 loci. They further determined programmed cell-death ligand-1 (PD-L1) expression by IHC, with > 1% tumor cells (TCs) or tumor-infiltrating lymphocytes (TILs) scoring positive. In IO biomarkers, deep sequencing showed significant differences among the three major subtypes of bladder carcinomas. They found that UC and SCC displayed higher frequencies of PD-L1 expression and higher TMB than ACB, and SCC has the highest frequency of CD274 amplification. In addition, the appearance of pure SCC features should not disqualify individuals for inclusion in IO trials.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen